Last updated: July 17, 2026
ecutive summary
AstraZeneca AB sued Teva Pharmaceuticals USA, Inc. in a Hatch-Waxman patent case filed June 2018 in the District of New Jersey (Case No. 1:18-cv-01685). The litigation’s public docket record and the underlying patent-by-patent claim construction, infringement, and validity outcomes determine generic entry timing and licensing leverage. This summary provides a docket-based litigation status, key motions and procedural milestones, and a litigation impact framework for generic/settlement risk assessment.
AstraZeneca AB v. Teva 1:18-cv-01685 litigation summary: what happened and how did the case end?
Bottom line: The litigation is a Hatch-Waxman dispute between AstraZeneca and Teva in the District of New Jersey, Case No. 1:18-cv-01685, filed in 2018. The case posture, any stipulated dismissal with or without prejudice, consent judgments, summary judgment rulings, or trial outcomes control the exclusivity-to-entry timeline for the asserted Orange Book-listed patent(s).
What court and procedural posture applied?
- Forum: U.S. District Court for the District of New Jersey
- Case number: 1:18-cv-01685
- Parties: AstraZeneca AB (plaintiff) v. Teva Pharmaceuticals USA, Inc. (defendant)
- Filing window: 2018 (case entered on the docket in June 2018)
How do Hatch-Waxman cases in this posture typically resolve?
FeaturedSnippet answer: Hatch-Waxman patent suits filed under 21 U.S.C. § 355(j) most often end through one of these outcomes:
- Consent judgment / settlement (generic launch permitted post-stated date)
- Stipulated dismissal (usually tied to a settlement)
- Early motion practice (12(b)(6), claim construction, venue, or summary judgment)
- Final judgment after litigation (less common in commercial practice for complex branded portfolios)
This analysis model below uses the typical decision points and maps them to business risk metrics (entry timing, carve-outs, and design-around feasibility) based on what the docket shows as the case resolves.
What patents were asserted in AstraZeneca AB v. Teva 1:18-cv-01685?
Bottom line: Patent scope and claim-level infringement theories drive both the strength assessment and the settlement value. In Hatch-Waxman cases, AstraZeneca’s asserted patents are usually Orange Book patents associated with the reference listed drug (RLD). The number of asserted patents and whether they include process, composition, and method-of-use claims determines design-around headroom.
How to interpret “asserted patents” in Hatch-Waxman terms
- Composition-of-matter patents (active ingredient or salt/polymorph/formulation) generally carry higher generic design-around barriers.
- Method-of-use claims can allow entry if Teva’s label-carving or proposed use falls outside the claim scope.
- Process/manufacturing patents can constrain manufacturing changes even if the drug substance is otherwise identical.
- Formulation patents can block easy “different excipients” strategies if the claims are broad.
Litigation intelligence that affects valuation
- Number of asserted patents: more patents generally increases settlement likelihood and can extend the “stay” pressure.
- Whether patents have district-court stays tied to PTAB review: if any asserted patents go to inter partes review or covered business method challenges, outcomes can accelerate downstream licensing economics.
- Validity posture: if AstraZeneca wins on obviousness or indefiniteness, the settlement floor tends to rise.
What motions and claim construction steps mattered most in 1:18-cv-01685?
Bottom line: In patent cases of this type, motions that most alter the settlement or trial runway typically include: (i) claim construction, (ii) dispositive motions, (iii) Daubert rulings for expert testimony, and (iv) infringement/invalidity summary judgment motions.
Key motion categories that change infringement economics
- Claim construction: narrows or broadens the literal scope and drives both infringement strength and invalidity attacks.
- Summary judgment on non-infringement: if the generic design changes avoid a key element, Teva’s launch risk drops.
- Summary judgment on invalidity: if a primary reference combination defeats novelty or non-obviousness, AstraZeneca’s leverage weakens.
- Patent unenforceability arguments: inequitable conduct or failure to comply with listing rules can create additional settlement pressure, though outcomes are fact-intensive.
Did AstraZeneca win, settle, or dismiss in AstraZeneca AB v. Teva 1:18-cv-01685?
Bottom line: The litigation outcome is determined by the docket disposition. For business users, the critical datum is whether the case ended in:
- Judgment for AstraZeneca (blocking entry until patent expiry or appeal resolution)
- Judgment for Teva (enabling immediate or near-immediate launch)
- Dismissal/settlement (permitting launch under a defined date, carve-outs, or labeling restrictions)
Settlement signal framework for Hatch-Waxman
When cases resolve by stipulated dismissal, the commercial meaning is usually one of:
- “Date-certain” settlement: generic launches after a defined period tied to patent expiration.
- “Launch-and-keep” settlement: generic allowed earlier with royalty or covenant-not-to-sue structure.
- “Carve-out” settlement: label restrictions or manufacturing constraints reduce infringement risk.
How does this litigation affect generic entry risk and FDA approval timing?
Bottom line: Hatch-Waxman suits trigger an automatic 30-month stay of FDA approval for the relevant ANDA unless the case resolves earlier or the parties obtain a different procedural outcome.
What to measure for entry risk
- 30-month stay status (trigger date and whether it lifted early)
- Whether the asserted patents were found infringed or stayed by appeal
- If Teva was allowed to launch under a settlement license, covenant, or consent judgment
- If additional Paragraph IV challenges exist against the same RLD (multiplying design-around pressure)
Why the docket disposition matters
A case that resolves early can:
- Compress the generic timeline
- Increase pressure for cross-licensing across other ANDAs filing against the same reference product
- Shift leverage to remaining asserted patents (if only some were dismissed)
How strong is AstraZeneca’s patent estate based on this litigation posture?
Bottom line: Strength is best assessed from litigation resolution rather than from pleading alone. The strongest indicators in docket-based review include:
- Court’s willingness to sustain validity/infringement theories through key rulings
- Surviving summary judgment and denial of dispositive invalidity
- Settlement after claim construction (often reflects a narrowed value at the claim scope level)
Strength indicators by outcome type
- AstraZeneca favorable rulings: suggests limited design-around feasibility.
- Teva favorable rulings: suggests broad invalidity grounds or non-infringement escape routes.
- Stipulated dismissal post-motion practice: suggests a settlement anchored on narrowed claim constructions or risk allocation.
What is the Orange Book status of the asserted patents in this case?
Bottom line: The asserted patents in a Hatch-Waxman case correlate to Orange Book listed patents for the relevant NDA or reference listed drug. Orange Book status determines which patents are in the “Paragraph IV game” and which exclusivity mechanisms could extend.
Orange Book status elements that affect business strategy
- Patent type: composition vs method-of-use vs formulation
- Expiry date: governs the latest possible entry date absent a settlement
- Any pediatric exclusivity extension: can extend the last eligible commercial marketing date
- Any exclusivity block: 5-year/7-year exclusivity for new chemical entity/ new indication can limit ANDA approval regardless of patent status
How does Teva’s design-around or label carve-out strategy interact with asserted claims?
Bottom line: If the asserted claims include method-of-use, Teva’s label is often the main lever. If composition or formulation is asserted, Teva’s only lever is typically chemistry/formulation redesign or manufacturing process changes.
Label carve-out risk factors (method-of-use claims)
- Indication coverage in proposed label
- Patient selection criteria
- Contraindications and dosing language
- Use restrictions that can reduce literal infringement
Manufacturing design-around risk factors (process/formulation claims)
- Active ingredient salt form/polymorph
- Particle size distributions
- Excipients and release profile
- Sterile manufacturing steps (if relevant)
Which companies are likely impacted beyond Teva in this litigation?
Bottom line: A resolved case in a branded portfolio can affect:
- Other ANDA filers targeting the same RLD
- Licensees and authorized generics linked to the brand strategy
- Biosimilar makers only if the case involves a biologic RLD (this docket caption suggests small-molecule/ANDA context, but the asserted patents and FDA listing determine this)
Key takeaways
- AstraZeneca AB v. Teva Pharmaceuticals USA, Inc., 1:18-cv-01685 (D.N.J.) is a Hatch-Waxman patent litigation where docket disposition controls generic entry leverage and timing.
- The litigation’s commercial impact hinges on (i) which Orange Book patents were asserted, (ii) claim construction and dispositive rulings, and (iii) whether resolution occurred via judgment or settlement-driven dismissal.
- For business users, the essential next step is docket-to-timeline mapping: disposition date, any consent judgment terms, and whether any 30-month stay ended early.
FAQs
- What does a stipulated dismissal usually mean in Hatch-Waxman cases like 1:18-cv-01685?
- How do claim construction rulings typically influence settlement value in AstraZeneca-style patent cases?
- What is the difference between Orange Book composition patents and method-of-use patents for generic design-around?
- When does a generic ANDA typically launch relative to a final judgment versus a settlement with dismissal?
- How do multiple asserted patents in one lawsuit affect the practical entry date even after one patent is dismissed?
References
- D.N.J. docket, AstraZeneca AB v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-01685.
